The market is also upbeat about Organon’s recently acquired regulatory and commercial rights in the United States for TOFIDENCE from Biogen Inc. TOFIDENCE is the first approved tocilizumab ...

JERSEY CITY, N.J., April 01, 2025--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. JERSEY CITY ...

Organon OGN shares soared 8.5% in the last trading session to close at $12.64. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Ellucian, the leading tertiary education technology solutions provider, today announced a new alliance with KPMG Australia. This alliance will help Australian institutions streamline operations and ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Attorney General Kwame Raoul today announced $24 million from the 2023 Juul Labs settlement will support efforts by Truth Initiative, the country's largest nonprofit public health organization ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The intravenous biosimilar of IL-6 inhibitor Actemra (tocilizumab) – called Tofidence (formerly BIIB800) – has been cleared for three of the indications for which Roche’s drug is used ...

Explore Organon stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for OGN. When it comes to dividend performers, healthcare usually takes a backseat to options ...